Ideaya Biosciences Inc (IDYA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ideaya Biosciences Inc (IDYA) Stock Forecast
Analysts expect Ideaya Biosciences (IDYA) to earn -$4.77 per share in the fiscal year ending Dec 31, 2026, on revenue of $42.40M. Of 16 analysts, 15 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 94% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 18.8% |
| Buy | 12 | 75.0% |
| Hold | 1 | 6.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 16
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 193.5%.
- Fiscal year ending Dec 31, 2026
- -$4.77
- EPS consensus, revenue $42.40M
- Fiscal year ending Dec 31, 2027
- -$4.15
- EPS consensus, revenue $124.45M
- Next report
- Feb 15, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.77 | -$5.05 to -$4.48 | 11 | $42.40M | $25.66M to $75.70M | 15 |
| Dec 31, 2027 | -$4.15 | -$5.46 to -$2.47 | 13 | $124.45M | $17.70M to $264.86M | 16 |
Quarterly Estimates
The EPS consensus rises from -$1.25 for the quarter ending Dec 31, 2026 to -$1.24 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.25 | -$1.42 to -$0.87 | 17 | $16.56M | N/A | 16 |
| Mar 31, 2027 | -$1.24 | -$1.41 to -$1.04 | 6 | $9.23M | N/A | 8 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 2 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.61.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.77 | -$4.59 | -$4.58 | -$4.61 | -$4.61 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.15 | -$4.11 | -$4.01 | -$4.10 | -$4.11 | N/A |
| Quarter ending Mar 31, 2027 | -$1.24 | -$1.21 | -$1.15 | -$1.19 | -$1.18 | N/A |
Frequently Asked Questions About IDYA
What is the IDYA stock forecast?
Consensus analyst estimates put Ideaya Biosciences's EPS at -$4.77 for the fiscal year ending Dec 31, 2026, on revenue of $42.40M. The consensus rating from 16 analysts is Buy.
How do analysts rate IDYA stock?
Of 16 analysts covering Ideaya Biosciences, 3 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IDYA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.77, with estimates from -$5.05 to -$4.48 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.15, with estimates from -$5.46 to -$2.47 from 13 analysts.
What revenue do analysts expect from Ideaya Biosciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $42.40M, with estimates from $25.66M to $75.70M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $124.45M, with estimates from $17.70M to $264.86M.
How many analysts cover IDYA?
16 analysts rate Ideaya Biosciences stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IDYA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors